Capricor Therapeutics Soars 94% Intraday on FDA Reversal for Duchenne Muscular Dystrophy Drug
Capricor Therapeutics (CAPR) surged 94% intraday after the FDA indicated willingness to review additional deramiocel data
Key points
- Capricor Therapeutics soars 94% on FDA willingness to review deramiocel Duchenne treatment data
- Rare FDA regulatory reversal transforms deramiocel approval probability and creates transformative revenue opportunity
- Watch: FDA data submission date, acceptance letter, and PDUFA review date for approval timeline
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇮🇳 India Stocks Regulatory biotech pharma healthcare